These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7000347)

  • 21. Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
    Ohnoshi T; Hayashi K; Ueno K; Tada A; Mizuta J; Tagawa S; Matsutomo S; Saito S; Kawashima K; Yoshino T
    Int J Hematol; 1993 Aug; 58(1-2):93-8. PubMed ID: 7693030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy.
    Zinzani PL; Martelli M; Bendandi M; De Renzo A; Zaccaria A; Pavone E; Bocchia M; Falini B; Gobbi M; Gherlinzoni F; Stefoni V; Tani M; Tura S
    Haematologica; 2001 Feb; 86(2):187-91. PubMed ID: 11224489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
    Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
    Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
    Durant JR; Gams RA; Bartolucci AA; Dorfman RF
    Cancer Treat Rep; 1977 Sep; 61(6):1085-96. PubMed ID: 332345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 36. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study.
    Grozea PN; Jones SE; McKelvey EM; Coltman CA; Fisher R; Haskins CL
    Cancer Treat Rep; 1979 Apr; 63(4):647-53. PubMed ID: 87277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
    Armitage JO; Dick FR; Corder MP; Garneau SC; Platz CE; Slymen DJ
    Cancer; 1982 Nov; 50(9):1695-702. PubMed ID: 6749279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
    Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D
    J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.
    Goldhirsch A; Pirovino M; Sonntag RW; Tschopp L; Ryssel HJ; Brunner KW
    Cancer Treat Rep; 1980; 64(2-3):335-7. PubMed ID: 6157468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
    Weick JK; Antunez A; Kraus TA; Fabian CJ; Dixon D
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1205-7. PubMed ID: 6347997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.